Abstract
Introduction: Coenzyme Q10 (CoQ10) is an antioxidant that enhances the activity of complex I and II in the Electron Transport Chain. Many preclinical and clinical studies evaluated CoQ10 for neuroprotection against Parkinson's disease (PD). The aim of this study is to synthesize evidence from published randomized controlled trials (RCTs) about the benefit of CoQ10 supplementation for patients with Parkinson's disease.
Methods: We followed the PRISMA statement guidelines during the preparation of this systematic review and metaanalysis. A computer literature search for (PubMed, EBSCO, Web of science and Ovid Midline) was carried out. We included RCTs comparing CoQ10 with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, UPDRS III and Schwab and England scores were pooled as standardized mean difference (SMD) between two groups from baseline to the endpoint.
Results: Five RCTs (981 patients) were included in this study. The overall effect did not favor either of the two groups in terms of: total UPDRS score (SMD -0.05, 95%CI [-0.10, 0.15]), UPDRS I (SMD -0.03, 95% CI [-0.23, 0.17]), UPDRS II (SMD -0.10, 95%CI [-0.35, 0.15]), UPDRS III (SMD -0.05, 95%CI [-0.07, 0.17]) or Schwab and England score (SMD 0.08, 95%CI [-0.13, 0.29]).
Conclusion: CoQ10 supplementation does not slow functional decline nor provide any symptomatic benefit for patients with Parkinson's disease.
Keywords: Coenzyme Q10, Parkinson's disease, neuroprotection, oxidative stress.
CNS & Neurological Disorders - Drug Targets
Title:Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis
Volume: 15 Issue: 1
Author(s): Ahmed Negida, Ahmed Menshawy, Gehad El Ashal, Yasmin Elfouly, Yasmein Hani, Yasmin Hegazy, Samar El ghonimy, Samar Fouda and Yomna Rashad
Affiliation:
Keywords: Coenzyme Q10, Parkinson's disease, neuroprotection, oxidative stress.
Abstract: Introduction: Coenzyme Q10 (CoQ10) is an antioxidant that enhances the activity of complex I and II in the Electron Transport Chain. Many preclinical and clinical studies evaluated CoQ10 for neuroprotection against Parkinson's disease (PD). The aim of this study is to synthesize evidence from published randomized controlled trials (RCTs) about the benefit of CoQ10 supplementation for patients with Parkinson's disease.
Methods: We followed the PRISMA statement guidelines during the preparation of this systematic review and metaanalysis. A computer literature search for (PubMed, EBSCO, Web of science and Ovid Midline) was carried out. We included RCTs comparing CoQ10 with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, UPDRS III and Schwab and England scores were pooled as standardized mean difference (SMD) between two groups from baseline to the endpoint.
Results: Five RCTs (981 patients) were included in this study. The overall effect did not favor either of the two groups in terms of: total UPDRS score (SMD -0.05, 95%CI [-0.10, 0.15]), UPDRS I (SMD -0.03, 95% CI [-0.23, 0.17]), UPDRS II (SMD -0.10, 95%CI [-0.35, 0.15]), UPDRS III (SMD -0.05, 95%CI [-0.07, 0.17]) or Schwab and England score (SMD 0.08, 95%CI [-0.13, 0.29]).
Conclusion: CoQ10 supplementation does not slow functional decline nor provide any symptomatic benefit for patients with Parkinson's disease.
Export Options
About this article
Cite this article as:
Negida Ahmed, Menshawy Ahmed, El Ashal Gehad, Elfouly Yasmin, Hani Yasmein, Hegazy Yasmin, El ghonimy Samar, Fouda Samar and Rashad Yomna, Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis, CNS & Neurological Disorders - Drug Targets 2016; 15 (1) . https://dx.doi.org/10.2174/1871527314666150821103306
DOI https://dx.doi.org/10.2174/1871527314666150821103306 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Role of APP and Aβ in Synaptic Physiology
Current Alzheimer Research Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Vascular Dementia: Atherosclerosis, Cognition and Alzheimers Disease
Current Alzheimer Research Properties of CA3 Dendritic Excrescences in Alzheimers Disease
Current Alzheimer Research Bone Marrow-Derived Mesenchymal Stem Cells Attenuate Amyloid β-Induced Memory Impairment and Apoptosis by Inhibiting Neuronal Cell Death
Current Alzheimer Research Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology Regional Grey Matter Loss and Brain Disconnection Across Alzheimer Disease Evolution
Current Medicinal Chemistry Advances in Studies on Neurodegenerative Diseases and their Treatments
Current Topics in Medicinal Chemistry Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Current Protein & Peptide Science Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Psychological Problems in Female Fragile X Premutations Carriers
Current Psychiatry Reviews The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design Functional Genomics Approach for Identification of Molecular Processes Underlying Neurodegenerative Disorders in Prion Diseases
Current Genomics Minocycline Mediated Mitochondrial Cytoprotection: Premises for Therapy of Cerebrovascular and Neurodegenerative Diseases
Current Drug Targets Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Commentary Research Highlights (Amyloid and Alzheimer's Disease: Easing the Load)
CNS & Neurological Disorders - Drug Targets